TIGIT and neoplasm: CD3+ and CD11B+ splenocytes showed a similar trend of TIGIT expression, although less pronounced compared with the tumor (1.3% vs 0.86% CD3+p = 0.0456 and 2.7% vs 2.1% CD11B+p = 0.0117), (Fig. 5A and Supplementary Figures S5, S6).